Boehringer Ingelheim and Eli Lilly and Co. (LLY) announced Tuesday that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose triple combination tablet of empagliflozin, linagliptin and metformin extended release (XR) for the treatment of adults with type 2 diabetes.
from RTT - Biotech http://bit.ly/317e2Vo
via IFTTT
No comments:
Post a Comment